Highlights

  • Vitrafy Life Sciences entered a Partnership with Hoxworth Blood Center to trial its red-cell cryopreservation technology.
  • The agreement represents the company's second U.S. blood-centre partnership following an earlier Vitalant collaboration.
  • Vitrafy's cryopreservation system is designed to extend red blood cell storage beyond standard refrigerated shelf life.
  • The company reported cash and term deposits of approximately $41.2 million at the end of FY26.

Vitrafy Life Sciences (ASX:VFY) has expanded its U.S. blood-sector presence through a partnership with Hoxworth Blood Center to trial its cryopreservation technology for red blood cells.

The agreement, announced on 23 July 2026, represents the second U.S. blood-centre collaboration for Vitrafy following an earlier partnership with Vitalant Innovation Center.

The arrangement is structured as an initial pilot rather than a revenue-generating contract, with Vitrafy aiming to demonstrate its technology within established blood collection networks and progress toward future commercial adoption.

What Was Announced?

Under the agreement, Vitrafy will install one of its cryopreservation freezing units and associated software at Hoxworth during the first half of FY27.

Cryopreservation involves freezing red blood cells using a cryoprotectant process, allowing storage for extended periods compared with standard refrigerated blood storage.

Longer storage capability can support applications including emergency reserves, military Supply chains and rare blood-type inventory management.

Hoxworth Blood Center, founded in 1938, operates seven permanent collection sites and supplies more than 31 hospitals across Ohio, Kentucky and Indiana.

Both organisations will contribute resources and in-kind support to the pilot program.

The agreement does not disclose contract value, Revenue arrangements or a confirmed timeline for conversion into a commercial relationship.

Why This Matters

For Vitrafy (ASX:VFY), establishing relationships with major U.S. blood centres is an important step in developing acceptance for its cryopreservation platform.

The U.S. blood sector is undergoing changes as existing preservation technologies approach transition periods, creating interest in alternative approaches for extending blood product storage.

A successful pilot at Hoxworth could provide additional validation of Vitrafy's technology and support future discussions with other blood centres.

However, the partnership remains an evaluation program rather than a commercial agreement. Adoption by blood centres requires technical validation, operational integration and regulatory acceptance.

Company Background

Vitrafy Life Sciences (ASX:VFY) is an Australian biotechnology company developing cryopreservation technology for blood products including red blood cells and platelets.

Its platform combines specialised freezing hardware with software designed to manage preservation and thawing processes.

The company is also developing applications in animal health, including aquaculture projects involving salmon milt preservation.

Vitrafy has conducted platelet preservation testing with the U.S. Army Institute of Surgical Research (USAISR) as part of broader validation activities.

The company is focused on building a U.S. market presence for its blood preservation technology.

Financial Position

Vitrafy ended FY26 with cash and term deposits of approximately $41.2 million following a $32 million Capital raising completed earlier in the year.

The company's core blood cryopreservation Business remains pre-revenue.

Its animal health division generated approximately $160,000 in Q4 FY26 revenue, with aquaculture processing volumes increasing 68% year-on-year to 1,250 salmon milt packs processed domestically.

The available cash position provides funding capacity for U.S. pilot installations and continued technology development activities.

What Comes Next?

The next milestone for Vitrafy (ASX:VFY) is installation of the cryopreservation equipment and software package at Hoxworth during the first half of FY27.

Investors will monitor results from the pilot program and whether the relationship progresses into a commercial agreement.

Additional areas of focus include potential expansion of blood-centre partnerships, further regulatory progress and continued validation of platelet and other blood-product preservation applications.

Risks

Vitrafy (ASX:VFY) faces commercial adoption risks because pilot partnerships do not guarantee conversion into revenue-generating contracts. Blood centres operate in a highly regulated environment, and adoption of new preservation technology may require extended validation periods. The company also faces competition from alternative preservation methods and depends on institutional acceptance in the U.S. market. As its primary blood business remains pre-revenue, funding requirements and execution of Manufacturing and deployment activities remain important considerations.

Investor Takeaway

The Hoxworth partnership expands Vitrafy's presence among U.S. blood centres and provides another opportunity to validate its cryopreservation technology.

The agreement represents commercial engagement rather than confirmed revenue, with no contract value or conversion timeline disclosed.

For Vitrafy (ASX:VFY), the key milestones ahead are pilot outcomes, potential commercial agreements with Hoxworth or Vitalant, additional blood-centre partnerships and progress toward broader adoption of its preservation platform.